Short answer
Sana Biotechnology, Inc. (SANA) filed an 8-K current report with the SEC on April 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Steven D. Harr, M.D. reclassified from Class I to Class III director.
Sana Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Steven D. Harr, M.D. reclassified from Class I to Class III director
- Board now evenly balanced with three directors in each of Classes I, II, and III
- No change in board membership or continuity of service
- Class III term expires at the 2027 annual meeting, advancing Harr’s scheduled re-election timing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sana Biotechnology, Inc. 8-K filings
Get the next SANA 8-K as it lands
Follow SANA for push alerts, or ask the research agent what this filing means.